Maynard Um
-
-
-
-
-
-
-
Longeveron selected for Alzheimer's poster at CTAD 2025 conference
-
-
-
-
-
-
-
Longeveron (LGVN) Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel in Alzheimer’s Disease
-
-
-
-
-
-
-
Longeveron (LGVN) Granted FDA Fast Track Designation for Lomecel-B
-
-
-
-
425,329 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

